human
plasma
consist
mainli
larg
protein
vari
term
composit
concentr
physiolog
state
individu
alter
protein
concentr
reflect
current
state
individu
health
thu
may
util
valuabl
biomark
specif
biolog
process
diseas
twodimension
gel
electrophoresi
proven
valuabl
method
separ
comparison
complex
protein
mixtur
exampl
diseas
healthi
state
method
provid
inform
regard
variat
rel
quantiti
structur
intact
protein
procedur
util
prepar
sampl
critic
acquisit
highqual
result
discoveri
biomark
object
studi
review
prepar
method
plasma
particularli
design
improv
detect
protein
low
abund
plasma
use
anticoagul
proteas
inhibitor
collect
blood
remov
abund
protein
use
multicompon
immunodeplet
system
desalt
procedur
allow
us
compil
profil
protein
occur
low
concentr
plasma
improv
pattern
gener
human
plasma
rich
sourc
biochem
product
function
indic
physiolog
clinic
statu
patient
also
evid
highprotein
content
includ
protein
synthes
secret
shed
lost
bodi
cell
tissu
protein
concentr
plasma
control
tightli
balanc
physiolog
function
area
includ
immun
coagul
small
molecul
transport
inflamm
lipid
metabol
therefor
chang
plasma
protein
concentr
consid
reflect
current
state
health
recent
discoveri
biomark
blood
plasma
becom
subject
intens
attent
consider
advanc
thu
far
made
proteom
research
analysi
larg
number
protein
via
proteom
techniqu
greatli
acceler
abil
identifi
new
biomark
diseas
toxic
process
includ
cancer
diabet
stroke
kidney
diseas
exposur
aromat
hydrocarbon
howev
estim
protein
may
normal
present
plasma
concentr
would
vari
millimolar
concentr
albumin
femtomolar
concentr
low
abund
compon
major
potenti
diseas
biomark
may
present
extrem
low
concentr
within
plasma
thu
might
obscur
presenc
abund
protein
similar
characterist
plasma
contain
varieti
protein
wide
dynam
concentr
rang
twodimension
gel
electrophoresi
current
princip
techniqu
separ
complex
protein
mixtur
techniqu
protein
separ
combin
two
differ
electrophoret
method
isoelectr
focus
ief
first
dimens
protein
separ
accord
isoelectr
point
pi
sodium
dodecylsulfatepolyacrylamid
gel
electrophoresi
sdspage
second
dimens
protein
separ
accord
molecular
weight
gener
inform
regard
protein
modif
andor
express
level
chang
also
allow
isol
protein
milligram
amount
structur
analys
use
malditof
ms
esim
edman
microsequenc
techniqu
owe
advantag
use
extens
discoveri
new
biomark
exampl
biomark
identifi
via
provid
tabl
appli
complex
sampl
plasma
discoveri
biomark
critic
establish
sampl
prepar
procedur
order
obtain
highqual
result
import
compon
procedur
method
select
prepar
plasma
minim
loss
plasma
protein
deplet
highabund
protein
remov
contamin
may
interfer
analysi
solubil
protein
transform
physicochem
state
suitabl
analysi
review
attempt
provid
current
method
prepar
human
blood
plasma
analysi
especi
design
improv
detect
protein
lowabund
plasma
gener
procedur
plasma
prepar
analysi
shown
fig
procedur
involv
plasma
collect
deplet
highabund
plasma
protein
remov
contamin
may
interfer
analysi
solubil
protein
method
collect
plasma
sampl
great
import
composit
concentr
plasma
protein
vari
collect
method
blood
sampl
collect
within
blank
tube
without
addit
drawn
syring
via
vacuum
tube
contain
anticoagul
eg
ethylenediamin
tetraacet
acid
edta
heparin
citrat
may
also
either
store
room
temperatur
refriger
type
anticoagul
concentr
plasma
storag
method
ie
storag
durat
temperatur
treatment
proteas
inhibitor
cocktail
pic
time
supernat
decant
centrifug
sampl
number
freezethaw
cycl
etc
contribut
qualiti
blood
sampl
thu
affect
proteom
plasma
plasma
collect
pic
withstand
temporari
storag
c
temporari
storag
c
least
singl
freezethaw
cycl
also
vital
import
acquir
supernat
quickli
centrifug
addit
preanalyt
variabl
includ
sampl
handl
alter
lowmolecularweight
proteom
within
plasma
also
recommend
least
min
clot
time
prior
process
would
minim
differ
inher
overrid
effect
coagul
basi
use
activ
tube
promot
rapid
clot
marshal
et
al
determin
phenylmethylsulfonyl
fluid
pmsf
ethylenediamin
tetraacet
acid
affect
stabil
serum
sampl
shown
maldim
particular
evalu
differ
protein
serum
plasma
treat
differ
anticoagul
edta
citrat
heparin
publish
sever
research
serum
obtain
allow
blood
clot
prior
centrifug
mani
protein
involv
coagul
process
also
remov
clot
process
serum
prothrombin
cleav
thrombin
fibrinogen
remov
facilit
clot
format
limit
seri
protein
chang
includ
proteolyt
cleavag
occur
clot
process
although
mani
protein
involv
coagul
process
includ
prothrombin
disappear
procedur
mani
peptid
absent
plasma
detect
serum
identifi
coagul
studi
differ
human
serum
plasma
use
orthogon
intact
protein
analysi
system
ipa
sever
protein
includ
alpha
beta
gamma
fibrinogen
well
vitronectin
shown
attribut
coagulationassoci
protein
addit
protein
expect
deplet
coagul
process
gener
much
lower
serum
sampl
compar
edtaplasma
citrateplasma
tammen
et
al
report
peptidom
analysi
human
blood
specimen
varieti
artifici
peptid
deriv
peptid
releas
coagul
process
type
enzymat
activ
plasma
kalikrein
due
high
level
artifici
peptid
signal
conclud
use
serum
sampl
appropri
peptidom
studi
monooligo
biomark
discoveri
order
studi
plasma
proteom
blood
sampl
plasma
obtain
must
treat
anticoagul
treat
blood
sampl
centrifug
order
remov
blood
cell
therebi
leav
plasma
subsequ
studi
although
plasma
composit
resembl
serum
prefer
serum
proteom
studi
mani
although
laboratori
investig
constitu
reflect
patient
patholog
statu
close
serum
constitu
addit
chang
blood
constitu
avoid
via
care
select
control
type
concentr
employ
anticoagul
popular
anticoagul
edta
heparin
sodium
citrat
sever
report
chang
protein
express
pattern
occur
conjunct
anticoagul
treatment
citrat
edta
inhibit
coagul
enzymat
process
via
chelateform
iondepend
enzym
contrast
heparin
function
via
activ
antithrombin
iii
gener
mainten
hemostasi
balanc
coagul
fibrinolysi
essenti
requir
seri
enzymat
reaction
caus
sequenti
activ
inactiv
proteas
antibodi
base
monoclon
antibodi
high
specif
fail
remov
relat
fragment
target
protein
polyclon
antibodi
iggbas
system
deplet
multipl
protein
one
step
lack
reactiv
across
multipl
mammalian
speci
high
affin
high
specif
high
cost
low
sampl
capac
igybas
system
deplet
multipl
protein
one
step
high
cost
high
affin
high
specif
low
sampl
capac
high
reactiv
across
multipl
mammalian
speci
platelet
activ
caus
clot
format
accordingli
concentr
plasma
protein
depend
platelet
stabil
platelet
tend
stabl
citrat
anticoagul
edtatr
blood
slightli
less
stabl
howev
longer
time
period
mark
chang
becom
appar
elaps
time
prior
centrifug
increas
mani
protein
could
function
good
biomark
detect
rel
low
concentr
one
challeng
identif
specif
biomark
protein
remov
protein
high
concentr
interfer
sever
abil
detect
protein
lower
concentr
plasma
abund
plasma
protein
constitut
approxim
total
plasma
protein
core
plasma
protein
albumin
compris
approxim
plasma
protein
content
present
high
concentr
order
gl
princip
plasma
protein
present
order
gl
immunoglobulin
ig
includ
heavi
light
chainfibrinogen
transferrin
haptoglobin
lipoprotein
protein
would
constitut
princip
candid
remov
prior
perform
proteom
analysi
lowabund
protein
consider
number
attempt
made
remov
albumin
abund
protein
plasma
primari
approach
deplet
albumin
highabund
protein
report
follow
summar
tabl
affinitybas
method
sizebas
method
antibodybas
deplet
method
assess
affinitybas
method
predic
affin
albumin
cibracon
blue
cb
associ
dye
cb
dye
use
expressli
bind
albumin
also
bind
nad
fad
atp
bind
site
protein
via
ionic
hydrophob
interact
allow
cb
dye
bind
larg
number
protein
result
potenti
loss
protein
nonspecif
bind
probabl
includ
protein
bind
dye
well
minor
protein
bind
albumin
despit
high
degre
nonspecif
protein
bind
method
sever
advantag
includ
highload
capac
low
cost
due
rel
low
cost
dispos
prevent
crosscontamin
differ
sampl
gener
igg
remov
commonli
achiev
immobil
protein
protein
g
onto
affin
resin
bind
fc
region
igg
howev
protein
g
may
bind
immunoglobulin
subgroup
therebi
leav
portion
heterogen
abund
protein
behind
method
involv
use
proprietari
polypeptid
affin
matrix
peptidebas
affin
medium
remov
albumin
peptid
modifi
sequenc
fc
region
produc
protein
engin
effort
increas
albumin
bind
capac
employ
deplet
abund
protein
plasma
advantag
peptidebas
ligand
includ
low
cost
reproduc
steriliz
complet
defin
product
nonbiolog
origin
anoth
deplet
method
involv
use
centrifug
ultrafiltr
devic
separ
protein
size
effect
approach
howev
report
limit
ultrafiltr
membran
normal
pores
repres
averag
normal
distribut
smaller
larger
pore
somewhat
common
observ
suboptim
retent
rate
particularli
high
concentr
serum
sampl
therebi
highlight
limit
reproduc
antibodybas
deplet
method
recent
develop
describ
mani
research
individu
antibodi
method
proven
specif
deplet
target
protein
result
complet
remov
abund
protein
monoclon
antibodi
appear
repres
promis
option
deplet
highabund
protein
use
target
specif
epitop
protein
therebi
result
remov
target
protein
howev
techniqu
may
appropri
recognit
form
target
protein
due
presenc
proteolyt
fragment
posttransl
modif
ptm
glycosyl
phosporyl
disrupt
antigenbind
site
partial
complet
unfold
protein
occlus
epitop
result
proteinprotein
interact
polyclon
antibodi
hand
like
deplet
multipl
structur
form
protein
desir
deplet
mani
highabund
protein
possibl
minim
incident
loss
nontarget
protein
recent
deplet
system
use
sever
polyclon
antibodi
high
specif
develop
remov
multipl
protein
simultan
rapid
effici
manner
immunodeplet
system
base
igg
igi
antibodi
rel
popular
method
may
result
polyclon
immunoglobin
ligand
immunodeplet
system
base
igg
capabl
simultan
remov
six
abund
protein
human
plasma
albumin
immunoglobulin
g
igg
immunoglobulin
iga
haptoglobin
transferrin
use
highspecif
rabbit
polyclon
antibodi
method
capabl
deplet
highabund
protein
includ
differ
molecular
form
mani
proteolyt
product
protein
coupl
low
nonspecif
loss
protein
rapidli
effici
singl
purif
step
immunodeplet
system
base
igi
employ
chicken
antibodi
orient
antibodi
antigenbind
site
face
outward
constant
portion
antibodi
coval
coupl
solid
phase
materi
permit
maximum
antigen
bind
effici
system
also
allow
deplet
human
albumin
igg
iga
igm
fibrinogen
transferrin
deplet
albumin
varieti
mammalian
speci
princip
disadvantag
antibodybas
deplet
includ
rel
high
cost
low
sampl
capac
fortun
antibodi
highli
robust
protein
appear
like
system
last
mani
purif
cycl
appropri
care
taken
minim
proteolysi
column
clog
multicompon
immunoaffin
column
recent
becom
commerci
avail
although
commerci
kit
rel
expens
also
quit
conveni
use
small
sampl
appli
electrophoret
gel
regard
format
approach
deplet
albumin
highabund
protein
use
spincolumn
format
chromatographi
format
previous
util
spincolumn
format
reagent
regener
mani
time
deplet
sampl
multipl
sampl
proper
column
wash
addit
polyclon
antibodi
resin
also
function
effect
spin
column
format
allow
parallel
process
multipl
sampl
aliquot
requir
complex
instrument
liquid
chromatographi
column
format
also
amen
autom
highthroughput
scale
order
analyz
clinic
sampl
speed
reproduc
crucial
accumul
statist
reliabl
inform
deplet
one
method
allow
screen
lowabund
protein
plasma
deplet
also
result
risk
lose
protein
interest
specif
target
deplet
albumin
plasma
transport
protein
bind
larg
number
compound
includ
hormon
cytokin
lipoprotein
amino
acid
remov
plasma
may
also
result
remov
lowabund
protein
attempt
recov
low
abund
protein
immunoaffin
column
previous
involv
use
mild
solvent
saltout
prepar
molecular
siev
filtrat
peptidebas
affin
medium
analysi
plasma
shown
especi
difficult
due
mani
compon
bind
protein
hydrolysi
protein
fragment
interfer
charg
molecul
use
analysi
addit
plasma
fraction
deplet
highabund
protein
may
dilut
highsalt
buffer
therefor
possibl
substancesprincip
proteas
salt
lipid
polysaccharid
nucleic
acidsshould
elimin
plasma
protein
concentr
small
volum
prior
applic
electrophoresi
proteas
plasma
must
inactiv
order
prevent
degrad
protein
whole
procedur
plasma
prepar
might
result
artifici
electrophoresi
spot
proteas
inhibitor
extens
use
inactiv
proteas
fact
gener
protocol
plasma
sampl
includ
applic
proteas
inhibitor
cocktail
pic
hulm
et
al
report
inclus
pic
plasma
sampl
result
stabl
reliabl
human
plasma
sampl
yield
reproduc
result
proteom
analysi
howev
proteas
inhibitor
alway
recommend
may
modifi
protein
structur
induc
chang
charg
protein
molecul
proteas
also
less
activ
lower
temperatur
therefor
recommend
plasma
prepar
low
temperatur
possibl
gener
method
inhibit
proteas
activ
includ
boil
plasma
sampl
sd
buffer
absenc
urea
includ
highph
buffer
trisbas
inactiv
proteas
use
low
ph
precipit
proteas
use
icecold
tca
solut
major
sampl
buffer
denatur
activ
suffici
inhibit
proteas
activ
plasma
tcaaceton
precipit
proven
quit
use
minim
protein
degrad
proteas
remov
contamin
howev
incomplet
precipit
protein
resolubil
may
result
partial
loss
protein
interest
salt
ion
may
interfer
electrophoret
separ
case
may
induc
modif
protein
structur
electrophoresi
salt
ion
may
compet
protein
migrat
toward
electrod
therebi
interf
protein
focus
salt
may
also
increas
conduct
ief
gel
increas
current
protein
focus
occur
ion
move
end
ief
gel
time
requir
ief
prolong
salt
concentr
excess
mm
may
induc
electroendosmosi
result
uneven
distribut
water
within
gel
subsequ
format
dehydr
overhydr
zone
therefor
salt
must
remov
prior
load
ief
gel
salt
remov
plasma
via
dialysi
gel
filtrat
tcaaceton
precipit
use
centrifug
filter
devic
concentr
protein
eg
centricon
column
millipor
bedford
usa
pluson
clean
kit
amersham
bioscienc
uppsala
sweden
anoth
way
overcom
salt
interfer
dilut
sampl
critic
concentr
salt
salt
concentr
immobil
ph
gradient
ipg
strip
lower
mm
case
sampl
subject
ingel
rehydr
plasma
turbid
normal
caus
lipid
compon
triglycerid
phospholipid
sterol
concentr
vari
accord
health
diet
blood
donor
lipid
also
interfer
immunodeplet
procedur
ief
current
resolut
remov
lipid
blood
plasma
gener
accomplish
use
solubil
buffer
contain
strong
denatur
agent
throughout
sampl
prepar
procedur
aceton
precipit
four
volum
use
cold
aceton
c
least
h
highspe
centrifug
lipid
bind
protein
via
hydrophob
bond
affect
charg
molecular
weight
bond
broken
use
charg
compound
disrupt
hydrophob
interact
deterg
act
hydrophob
bond
enabl
stabl
dispers
hydrophob
residu
within
hydrophil
environ
sd
dithiothreitol
dtt
routin
util
treat
plasma
follow
min
heat
c
howev
neg
sd
charg
may
affect
pi
sampl
order
minim
advers
effect
sd
concentr
dilut
wv
via
addit
excess
amount
ionic
nonion
deterg
eg
nonidet
triton
cholamidoprophi
chap
prior
ief
lipid
extract
use
organ
solvent
eg
ethanol
aceton
mani
organicsolubl
contamin
includ
deterg
lipid
retain
organ
phase
howev
extract
method
result
sever
loss
protein
either
certain
protein
solubl
organ
solvent
precipit
protein
consist
resolubil
nucleic
acid
interact
protein
via
electrostat
interact
therebi
increas
viscos
sampl
solut
clog
pore
polyacrylamid
gel
prevent
ief
eventu
result
pattern
horizont
streak
gel
stain
follow
separ
nucleic
acid
gel
also
stain
result
background
smear
nucleic
acid
remov
digest
mixtur
proteasefre
rnase
dnase
ad
carrier
ampholyt
subsequ
ultracentrifug
precipit
basic
polyamin
highph
valu
tcaaceton
precipit
typic
tca
aceton
also
employ
remov
nucleic
acid
although
associ
risk
protein
loss
polysaccharid
also
interfer
ief
via
obstruct
gel
pore
ultracentrifug
use
remov
highmolecularweight
polysaccharid
precipit
tca
ammonium
sulfat
phenolammonium
acet
effect
remov
lowmolecularweight
polysaccharid
contamin
remov
plasma
protein
must
solubil
kept
solubl
within
particular
ph
throughout
separ
solubil
process
includ
denatur
protein
break
noncoval
bond
disulfid
bond
within
among
protein
addit
noncoval
bond
protein
nonprotein
includ
lipid
nucleic
acid
maintain
nativ
charg
molecular
weight
solubl
protein
end
process
hot
sd
method
classic
sampl
solubil
method
method
problemat
howev
anion
sd
may
interfer
protein
ief
protein
solubil
process
ampli
review
show
rieder
sampl
solut
firstdimens
separ
alway
involv
urea
neutral
chaotrop
denatur
protein
via
disrupt
noncoval
ionic
bond
amino
acid
residu
urea
may
includ
sampl
solut
concentr
urea
solut
howev
somewhat
unstabl
spontan
degrad
urea
cyanat
occur
room
temperatur
cyanat
ion
remov
posit
charg
amin
sulfhydryl
group
protein
process
known
carbamyl
therebi
affect
effici
ief
dtt
effect
cyanat
scaveng
rabilloud
et
al
report
util
thioureacontain
denatur
mixtur
protein
highli
prone
aggreg
use
thiourea
combin
urea
ief
particular
determin
improv
solubil
hydrophob
protein
thiourea
normal
use
concentr
combin
urea
howev
tend
inhibit
sdsprotein
bind
seconddimension
separ
result
poor
separ
gel
disulfid
bond
broken
via
addit
excess
thiolreduc
agent
eg
dtt
dithioerythritol
tri
phosphin
tributyl
phosphin
tbp
howev
portion
thiolreduc
agent
ioniz
basic
ph
enter
basic
end
gel
ruin
ph
gradient
therebi
disrupt
region
induc
reoxid
reduc
disufid
bond
order
inhibit
reoxid
requir
alkyl
thiol
group
result
prevent
precipit
protein
frequent
product
spuriou
spot
basic
ph
region
consequ
format
disulfid
bond
frequent
employ
reduct
dtt
administ
concentr
rang
mm
longer
wide
use
carrier
ampholyt
ief
tbp
appear
migrat
ief
use
separ
protein
unfortun
somewhat
difficult
handl
anion
deterg
sd
tradit
use
determin
interfer
ief
protein
state
previous
zwitterion
deterg
chap
current
common
deterg
util
standard
procedur
belong
class
linear
sulfobetain
surfact
includ
caprylyl
sulphobetain
amidosulfobetain
asb
carrier
ampholyt
also
augment
protein
solubl
via
minim
protein
aggreg
product
uniform
conduct
across
ph
gradient
without
disrupt
ief
alter
shape
gradient
carrier
ampholyt
small
solubl
amphoter
molecul
high
degre
buffer
capac
near
pi
voltag
appli
ief
carrier
ampholyt
move
closest
pi
result
continu
ph
gradient
ampholyt
may
util
concentr
high
vv
carrier
ampholyt
also
scaveng
cyanat
ion
facilit
precipit
nucleic
acid
centrifug
object
solubil
process
achiev
wellfocus
firstdimension
separ
ief
addit
solubl
problem
frequent
aris
ief
sampl
entri
solubl
isoelectr
point
problem
solv
use
commerci
ipg
gel
prepar
coval
incorpor
gradient
acid
basic
buffer
group
polyacrylamid
gel
gel
cast
procedur
case
buffer
base
ad
basic
condit
requir
promot
full
solubil
minim
proteolysi
base
buffer
dilut
mm
less
prior
load
sampl
onto
ief
discoveri
protein
biomark
plasma
repres
signific
technic
challeng
although
varieti
proteom
techniqu
attempt
far
gener
applic
techniqu
yet
develop
identif
biomark
replac
regard
abil
separ
display
sever
thousand
plasma
protein
simultan
select
appropri
blood
plasma
prepar
method
import
confid
result
use
anticoagul
proteas
inhibitor
blood
collect
increas
chanc
consist
result
remov
abund
protein
use
multicompon
immunodeplet
system
allow
us
compil
profil
protein
occur
low
concentr
plasma
desalt
aceton
precipit
improv
pattern
gener
although
may
result
loss
sever
protein
techniqu
harbor
promis
widespread
use
prepar
sampl
identif
biomark
use
earli
diseas
detect
well
monitor
diseas
progress
augment
accuraci
prognosi
use
human
blood
plasma
